ESMO Asia 2018 Congress: ESMO Colloquia

The ESMO Colloquia are innovative new sessions within the Congress programme that bring together top experts to discuss evolving areas of interest to the oncology community. 

The Colloquia are organised by ESMO and supported by the industry in a unique collaboration making them the perfect complement to the scientific and education programme of the Congress.

Friday, 23 November 2018

ESMO Colloquium: Immunotherapy of lung cancer:  Alone or in combination?

Immunotherapy of Lung Cancer: Alone or in Combination? Thumbnail

Room 311, 12:45-14:15
This educational activity is provided by ESMO and supported by Lilly and Roche.
View the ESMO Colloquium details

Learning Objectives

  • Review the optimal immunotherapy options for NSCLC in 1st line
  • Discuss the rationale for combining immune checkpoints (ICPs) among themselves or with cytotoxic drugs
  • Evaluate the role of anti-angiogenics in combination with chemotherapy and ICPs
  • Acquire knowledge of recent Guidelines on 1st line NSCLC with ICP treatment

Friday, 23 November 2018

ESMO Colloquium: Oncology biosimilars in Asia

Oncology Biosimilars in Asia Thumbnail

Hall 404, 16:30-18:00
This educational activity is provided by ESMO and supported by Amgen, MSD, Pfizer and Sandoz.
View the ESMO Colloquium details

Learning Objectives

  • Understand the state of play, in the Asia- Pacific community, concerning the development and uptake of oncology biosimilars (moAbs)
  • Inform the healthcare community about the existing challenges for the uptake of oncology biosimilars emerging from the recent survey conducted by ESMO
  • Discuss the example of India, a country producing biosimilars in the region
  • Assess the financial impact of oncology biosimilars on healthcare systems within the APAC region

Saturday, 24 November 2018

ESMO Colloquium: Updated therapeutic approach of castration-resistant prostate cancer (CRPC)

Updated Therapeutic Approach of Castration-Resistant Prostate Cancer (CRPC) Thumbnail

Room 324, 12:45-14:15
This educational activity is provided by ESMO and supported by Astellas.
View the ESMO Colloquium details

Learning Objectives

  • To review the peculiar aspects of CRPC
  • To evaluate the benefit of conventional chemotherapy in CRPC
  • To understand the impact of androgen receptor inhibition in CRPC
  • To get an update of potential development in immunotherapy of CRPC

Sunday, 25 November 2018

ESMO Colloquium: Metastatic gastric and oesophago-gastric cancers

Metastatic Gastric and Oesophagogastric Cancers Thumbnail

Room 324, 9:15-10:15
This educational activity is provided by ESMO and supported by Lilly.
View the ESMO Colloquium details

Learning Objectives

Review the optimal treatment options in 1st line according to the biomarker profile

  • Discuss treatment of patients fit for 2nd line, selection criteria, nutritional status impact
  • Learn about recent results of immunotherapy for metastatic gastric cancer
  • Acquire knowledge of recent Guidelines